Filtered By:
Management: Funding

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 373 results found since Jan 2013.

UArizona Health Sciences Researchers to Study Long COVID as Part of National Collaborative
This study of post-acute sequelae of SARS-CoV-2, which is aimed at understanding the reasons for persistence of symptoms and organ involvement, assumes tremendous importance for us to devise new treatments and cures to address the long-term consequences of this pandemic, " said Dr.Sairam Parthasarathy, one of the project ' s multiple principal investigators.In addition to Parthasarathy, who is a professor of medicine and chief of the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine at the UArizona College of Medicine – Tucson and a BIO5 Institute member, principal investigators include Dr.Marilyn Glassber...
Source: The University of Arizona: Health - December 16, 2021 Category: Universities & Medical Training Authors: mittank Source Type: research

Researchers to Study Why COVID-19 Strikes Asthma Sufferers Less Severely Than Others
A University of Arizona Health Sciences-led research team received $7.16 million in federal funding to study how to better control severe asthma and determine why sufferers are less likely to contract COVID-19, influenza and rhinovirus. Today University of Arizona Health Scienceswomen_blowing_nose-948301830-hero-web.jpgHealthCollege of Medicine - TucsonExpertsExplorationResearchAn investigation into why asthma sufferers are less likely to contract COVID-19 is one of several aims for research funded through a $7.16 million National Institutes of Health cooperative agreement with the  Asthma and Airway Disease Research ...
Source: The University of Arizona: Health - December 9, 2021 Category: Universities & Medical Training Authors: mittank Source Type: research

Magic Johnson ’s HIV Disclosure Helped to Shatter Stigmas. But 30 Years Later, Disparities in Treatment Remain
For many watching Earvin “Magic” Johnson on television on Nov. 7, 1991, his words were tantamount to an announcement of his own death sentence. In a press conference hastily convened by Johnson and the Los Angeles Lakers after a local media outlet got wind of the story, the 32-year-old NBA superstar revealed he was HIV positive. Dr. Michael Mellman, then the Lakers team physician, remembers a last-minute conversation with Johnson, just before they walked out to face a sea of cameras: “He looked at me and said, I just want to get this straight, I have HIV, not AIDS, right?” [time-brightcove not-tgx=...
Source: TIME: Health - November 4, 2021 Category: Consumer Health News Authors: Francine Uenuma Tags: Uncategorized COVID-19 HIV/AIDS nationpod NBA Sports Source Type: news

P075 partnering with school-based health centers: a sustainable model of community-based asthma care
There are many models of treating asthma in the community setting; most rely on grant monies to cover operating costs. When grant periods end and are not renewed, partnerships usually dissolve, to the detriment of the community. We sought to transition work with a community partnership from grant-funded to sustainable funding,
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: K. Rilett, N. Sherif, A. Go, J. Carlson, M. Huntwork Source Type: research

Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV
NEW BRUNSWICK, N.J., October 29, 2021 – Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robust immune response in both healthy adults and adults living with HIV. These findings, alongside Phase 3 data recently published in The Lancet Infectious Diseases, support the potential prophylactic use of the vaccine regimen to protect people at risk of acquiring Ebola. The regimen was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from th...
Source: Johnson and Johnson - October 29, 2021 Category: Pharmaceuticals Source Type: news

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med. 2021 Oct 18:S2213-2600(21)00384-2. doi: 10.1016/S2213-2600(21)00384-2. Online ahead of print.ABSTRACTBACKGROUND: Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19.METHODS: We did a double-blind, randomised, placebo-controlled trial at 63 hospitals across five countries (Japan, Mexico, Singapore, South Korea, and the USA). Eligible patients were hospita...
Source: Respiratory Care - October 21, 2021 Category: Respiratory Medicine Authors: Andre C Kalil Aneesh K Mehta Thomas F Patterson Nathaniel Erdmann Carlos A Gomez Mamta K Jain Cameron R Wolfe Guillermo M Ruiz-Palacios Susan Kline Justino Regalado Pineda Anne F Luetkemeyer Michelle S Harkins Patrick E H Jackson Nicole M Iovine Victor F Source Type: research

Socioeconomic disparities in asthma healthcare utilization, exacerbations and mortality: A systematic review and meta-analysis
Capsule summary: Patients from lower socioeconomic backgrounds have substantially increased secondary healthcare utilization. It is unclear to what extent this is driven by an increased risk of exacerbations or the funding model of their local healthcare system.
Source: Journal of Allergy and Clinical Immunology - October 17, 2021 Category: Allergy & Immunology Authors: Charlene Redmond, Abdul Qadr Akinoso-Imran, Liam G. Heaney, Aziz Sheikh, Frank Kee, John Busby Source Type: research

Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
NEW BRUNSWICK, N.J., September 13, 2021 – Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years. The data also showed that booster vaccination with Ad26.ZEBOV, administered to adults two years after the initial vaccination, induced a strong anamnestic (immune) response within seven days. These findings support the potential p...
Source: Johnson and Johnson - September 13, 2021 Category: Pharmaceuticals Source Type: news

COVID-19 pandemic: different roles for scientific publications and funding face to epidemiological data —an European, country-based perspective
COVID-19 has represented an unprecedented challenge to be faced also concerning the spread of information, with scientific literature being often the sole source of trustworthy knowledge for the global communi...
Source: Clinical and Molecular Allergy - September 13, 2021 Category: Allergy & Immunology Authors: Alessandro Tonacci, Sara Genovese, Giovanni Pioggia and Sebastiano Gangemi Tags: Commentary Source Type: research

NIH awards more than $20 million to international HIV database centers
(NIH/National Institute of Allergy and Infectious Diseases) NIH has renewed grants to seven regional centers that compose the International epidemiology Databases to Evaluate AIDS (IeDEA), awarding $20.8 million in first-year funding. The 15-year-old IeDEA program efficiently advances knowledge about HIV by pooling and analyzing de-identified health data from more than two million people with HIV on five continents to answer research questions that individual studies cannot address. The grants are expected to last five years and to total an estimated $100 million.
Source: EurekAlert! - Medicine and Health - July 22, 2021 Category: International Medicine & Public Health Source Type: news

Adjuvant developed with NIH funding enhances efficacy of India's COVID-19 vaccine
(NIH/National Institute of Allergy and Infectious Diseases) An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness. COVAXIN was developed and is manufactured in India, which is currently suffering a devastating health crisis due to COVID-19.
Source: EurekAlert! - Infectious and Emerging Diseases - June 29, 2021 Category: Infectious Diseases Source Type: news

What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news

Clinical Trial Evaluating Mixed COVID-19 Vaccine Schedules Begins
(NIH/National Institute of Allergy and Infectious Diseases) The National Institutes of Health has started a Phase 1/2 clinical trial in which adult volunteers who have been fully vaccinated against COVID-19 will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens. The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, is leading and funding the study through the Infectious Diseases Clinical Research Consortium, a clinical trials network.
Source: EurekAlert! - Infectious and Emerging Diseases - June 1, 2021 Category: Infectious Diseases Source Type: news

AAAAI Funding Opportunities
Source: Journal of Allergy and Clinical Immunology - May 26, 2021 Category: Allergy & Immunology Authors: Mitchell H. Grayson Source Type: research

Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Discussions are ongoing with the U.S. Food and Drug Administration regarding the approval of the vaccine regimen in the U.S. WHO Prequalification is often a prerequisite for national registrations of new vaccines and medicines in developing countries. Johnson & Johnson now looks forward to collaborating with the WHO’s African Vaccine Regulatory Forum (AVAREF) to progress national registrations of the Company’s Ebola vaccine regimen. The Company’s Ebola vaccine regimen is designed to be used proactively to induce immunity against Ebola virus disease in adults and children. Johnson & Johnson’s Commitment to E...
Source: Johnson and Johnson - May 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news